CERo Therapeutics Holdings, Inc. (CERO)

CERO Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021
Cash & Equivalents	0.1	42.14	19.22
Short-Term Investments	8.44	0	0
Cash & Cash Equivalents	8.53	42.14	19.22
Cash Growth	-79.75%	119.29%	-
Other Current Assets	0.03	0.23	0.31
Total Current Assets	8.56	42.37	19.52
Property, Plant & Equipment	0	0	4.65
Total Long-Term Assets	0	0	4.65
Total Assets	8.56	42.37	24.18
Accounts Payable	3.54	1.66	0.46
Current Debt	1.56	0.65	0.59
Other Current Liabilities	0.08	28.44	0.79
Total Current Liabilities	5.17	30.75	1.84
Long-Term Debt	0	0	3.02
Other Long-Term Liabilities	9.15	9.15	0.65
Total Long-Term Liabilities	9.15	9.15	3.66
Total Liabilities	14.32	39.9	5.5
Total Debt	1.56	0.65	3.6
Debt Growth	139.23%	-81.96%	-
Retained Earnings	-14.2	-11	-23.97
Shareholders' Equity	-14.2	-11	-23.43
Net Cash / Debt	6.98	41.49	15.62
Net Cash / Debt Growth	-83.18%	165.71%	-
Net Cash Per Share	1.07	1.84	1.74
Working Capital	3.39	11.62	17.69
Book Value Per Share	-2.17	-0.49	-2.61

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).